title: Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms.
abstract: The objectives of this study are to determine whether patients with overactive bladder (OAB) and nocturia achieved relief of their nighttime voiding symptoms when treated with solifenacin and whether having nocturnal polyuria (NP) affected that response. The patients pooled from four phase III clinical trials were evaluated for reductions in nocturia episodes after treatment with solifenacin (5 or 10 mg) or placebo. A second analysis was performed in patients with and without NP. The patients treated with solifenacin experienced statistically significant reductions in nocturia episodes; median reductions were -35.5% for 5 mg of solifenacin and -36.4% for 10 mg of solifenacin compared with -25.0% for placebo, and significantly more patients treated with solifenacin vs placebo achieved a mean nocturic frequency of <or=1 episode/night. Solifenacin significantly reduced nocturia episodes only in patients without NP (mean change was -0.61 episodes/night for both doses compared with -0.43 episodes for placebo). Solifenacin significantly improved nocturia symptoms only in OAB patients without NP.
authors.affiliation: Department of Obstetrics, Division of Female Pelvic Medicine and Reconstructive Surgery, Loyola University Medical Center, Building 103, Room 1004-D, 2160 South First Avenue, Maywood, IL 60153, USA. Lbrubaker@lumc.edu
authors.forename: Linda
authors.initials: L
authors.lastname: Brubaker
authors.forename: Mary P
authors.initials: MP
authors.lastname: FitzGerald
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D053158:Nocturia / Q000188:drug therapy*; D011141:Polyuria / Q000188:drug therapy*; D011812:Quinuclidines / Q000008:administration & dosage / Q000627:therapeutic use*; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
chemical_list: D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D000069464:Solifenacin Succinate